VIP: Mechanism of Action in Research Models

The VIP mechanism of action centers on two receptors and the cyclic AMP signals that follow. VIP stands for vasoactive intestinal peptide. It is a neuropeptide made of 28 amino acids. It belongs to the secretin and glucagon peptide family. It is found widely in the nervous system and the gut. This overview sums up how the peptide is tested in lab assays, cell cultures, and animal models. Read it strictly in a research context.

What is the VIP mechanism of action?

VIP works mainly by activating the VPAC1 and VPAC2 receptors. Both are class-B G-protein-coupled receptors, or GPCRs. They link mostly to a protein called Gs and to the enzyme adenylate cyclase.

When VIP binds, cyclic AMP rises inside the cell. This turns on protein kinase A and the signals below it. VIP also binds a related receptor, PAC1, but more weakly. That is why it is often studied beside a peptide called PACAP.

VIP is a natural ligand for these receptors. So it makes a handy reference agonist in receptor work. An agonist is a molecule that activates a receptor. Its specs are well documented:

• Molecular formula: C147H237N43O43S
• Molecular weight: about 3326.83 g/mol
• CAS number: 37221-79-7
• PubChem ID: 53314964

This fixed identity is part of why VIP is seen as a clean tool for class-B GPCR signaling.

A single, well-mapped target changes how the mechanism is studied. Some peptides act on many systems at once, so labs must rely on broad functional tests. VIP work can follow a clear chain of events instead:

1. VIP binds the receptor.
2. Gs links to adenylate cyclase.
3. Cyclic AMP rises.
4. Protein kinase A turns on.

This clear chain makes VIP useful in two ways. It is a subject of study in its own right. It is also the yardstick for testing engineered analogs and blockers.

What is the structure of VIP?

VIP is a strongly basic, linear peptide with 28 residues. It shares sequence features with PACAP and secretin. This structure lets it bind class-B GPCRs tightly.

These receptors have large outer domains. They grip peptide agonists in a typical two-part binding mode. VIP has a linear, unmodified form. That makes it a good natural ligand when a lab needs a reliable reference agonist.

Its place in the secretin and glucagon family is more than a label. It is why VIP is often compared with PACAP and secretin. Shared structure leads to shared receptor activity, though not identical activity.

PACAP shares enough sequence with VIP that both bind the VPAC receptors. So labs often study the two side by side. This helps them tie an effect to one peptide, not to the whole family.

The strongly basic, charged nature of VIP also affects how it is handled. A charged, linear peptide of this size readily sticks to surfaces and reacts with the buffer. So its behavior in an assay depends closely on how it was prepared. This link between structure, handling, and repeatable receptor activity comes up often in VIP work.

How does VIP signal through VPAC receptors and cAMP?

VIP research focuses on activation of VPAC1 and VPAC2. These receptors link mostly to Gs and adenylate cyclase. Activation raises cyclic AMP in the cell and drives protein kinase A signals.

Labs often study which subtype VIP acts through. VPAC1 and VPAC2 are found in different tissues, so the subtype matters.

This receptor-defined, cyclic AMP pathway sets VIP apart from peptides with no single known target. Labs that compare the two types often review the DSIP mechanism of action. For DSIP, no single receptor has been found, and functional tests stand in for binding data.

The weaker binding at PAC1 adds another layer. Studies that aim to isolate VPAC signals must allow for a possible PAC1 effect. This is another reason VIP and PACAP are so often tested together.

How is VIP studied in neuroimmune and smooth muscle models?

After receptor activation, VIP is studied for its effects on smooth muscle relaxation, secretion, and immune cells. It is studied as a modulator that can shift the balance of cytokines. Cytokines are small signaling proteins made by immune cells.

These tests show how one peptide, working through cyclic AMP, can reach many systems in controlled models. These include the heart and blood vessels, the gut, the airways, and the immune system.

The neuroimmune side is an especially active area. Labs use VIP to probe how peptide signals meet inflammatory pathways. Teams building wider nervous system panels sometimes cross-check other materials. Examples include the neurotrophic material Cerebrolysin and the anxiety-linked peptide Selank. Each one comes at nervous system signaling from a different angle.

What role does VIP play in circadian signaling?

VIP is also central to circadian research, the study of daily body clocks. The suprachiasmatic nucleus is the brain's master clock. Inside it, VIP signals through VPAC2. Labs study how this peptide signal helps keep the clock in sync.

Researchers use VIP to test how clock neurons link to each other under set conditions. This role is treated as a finding about mechanism, not a claim about the body. It shows how one VPAC pathway can be studied in very different tissues, from gut smooth muscle to clock neurons in the brain.

How should VIP mechanism data be read?

Current knowledge of VIP comes from in vitro assays, animal models, and published research. Findings should be read as results within their own test setting. They are not established physiological or clinical outcomes.

Reconstituted VIP is less stable than the freeze-dried powder. So repeatable results depend on careful preparation. Three pages help here:

• The VIP handling and reconstitution guide covers preparation and cold-chain practice.
• The VIP research applications overview covers study use.
• The VIP product page offers the peptide with a certificate of analysis checked by a third party.

For research use only. VIP is an investigational research peptide and is not approved for human or veterinary use. All descriptions refer to preclinical and in vitro laboratory research.